UBS Group
DICE

UBS Group’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

UBS Group’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,000
Closed -$1.16M – 10294
2023
Q2 		$1.16M Buy
+25,000
New +$864K ﹤0.01% 4100

UBS Group's DICE Position: Q3 2023 in Review

UBS Group sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 399,284 shares — an estimated $18.6M sold.

UBS Group first reported a position in DICE in Q4 2021 and held it in 6 quarters. The position peaked at $18.6M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • UBS Group reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 399,284 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $18.6M.
  • UBS Group first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • UBS Group's DICE Therapeutics, Inc. Common Stock position peaked at $18.6M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.